<DOC>
	<DOCNO>NCT01225874</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood bone marrow patient cancer laboratory may help doctor predict well patient respond treatment . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This trial study biomarkers classify young patient acute lymphoblastic leukemia ( ALL ) remission induction therapy young patient B-precursor ALL .</brief_summary>
	<brief_title>Biomarkers Classify Young Patients With Acute Lymphoblastic Leukemia ( ALL ) Remission Induction Therapy Young Patients With B-Precursor ALL</brief_title>
	<detailed_description>OBJECTIVES : - To provide clinical laboratory data necessary placing patient ALL onto proper therapeutic trial . ( Classification ) - To provide administrative base capture classification data correlative study ALL treatment protocol series historical protocol . ( Classification ) - To provide appropriate induction regimens patient may enter risk specific , post-induction therapeutic trial . ( Induction therapy ) - To determine correlation event-free survival ( EFS ) follow measure minimal-residual disease ( MRD ) /early response ( ER ) : 1 ) rate peripheral blast count disappearance absolute blast count day 8 determine morphologically , flow cytometry , use molecular technique ; 2 ) Marrow morphology day 8 , ; 3 ) MRD determine flow cytometry molecular technique bone marrow peripheral blood sample day 29 . ( Induction therapy ) OUTLINE : This multicenter study . - Classification study : Bone marrow peripheral blood sample collect may analyze B- T-lineage antigen screening ; cytochemical stain ; cytogenetics ( karyotype ) ; immunophenotype screening MLL , E2A-PBX1 , TEL-AML1 ; immunophenotype detection minimal-residual disease ( MRD ) ; FCM ploidy ( DNA index ) ; trisomies 4 10 ( FISH ) ; molecular testing BCR/ABL , MLL rearrangement , E2A-PBX1 , TEL-AML1 ; molecular detection MRD - Tγ , Tδ , IgH ; acute lymphoblastic leukemia ( ALL ) cell bank ; special T-ALL reference laboratory study ( role tumor suppressor gene T-ALL drug sensitivity profile T-ALL ) ; special study mature B-ALL [ ( 18 ; 14 ) ( a24 ; q32 ) ] FISH ; hematopathology consultation concern morphology cytochemistry . The immunophenotype result use assign patient treatment protocol , assign patient post-induction ( day 28 ) risk group treatment patient B-precursor ( non-T , non-B ) ALL , use reference laboratory MRD result . - Induction therapy study : Patients enter stratum 3 ( three drug ) NCI consensus standard-risk disease ( age &lt; 10 year WBC &lt; 50,000/mm³ ) stratum 4 ( four drug ) induction therapy NCI consensus high-risk disease ( age ≥ 10 year and/or WBC ≥ 50,000/mm³ CNS3 disease testicular disease ) . - Stratum 3 : Patients receive oral dexamethasone twice daily day 1-28 ; vincristine sulfate IV day 1 , 8 , 15 , 22 ; pegaspargase intramuscularly ( IM ) day 4 , 5 , 6 ; cytarabine intrathecally ( IT ) day 1 ; methotrexate IT day 8 ( patient also receive methotrexate IT day 15 22 ) . - Stratum 4 : Patients receive oral prednisone twice daily day 1-28 ; vincristine sulfate IV day 1 , 8 , 15 , 22 ; IM SC-PEG E. coli asparaginase IM day 2 , 5 , 8 , 12 , 15 , 19 ; daunorubicin hydrochloride IV 15-20 minute day 8 , 15 , 22 ; methotrexate IT day 1 8 ( patient also receive methotrexate IT day 15 22 ) . Based day 29 bone marrow result , patient may start consolidation therapy , undergo retesting week , receive 2 additional week therapy . Additional therapy comprise oral prednisone thrice daily 14 day ; vincristine sulfate IV daunorubicin hydrochloride IV 15-20 minute day 29 36 ; IM pegaspargase day 29 , 30 , 31 . After successful remission induction , patient assign COG-P9904 , COG-P9905 , COG-P9906 base classification study . Patients undergo bone marrow aspiration day 8 determine prognostic significance early remission context therapy . After completion study treatment , patient follow every 6 month 4 year annually thereafter .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meets one follow set criterion : Classification study : Newly diagnose ALL* Must one following : ≥ 25 % blast bone marrow ≥ 100,000/μl peripheral blood WBC ≥ 75 % blast , bone marrow aspiration omit reason medical contraindication ≥ 30,000/μl WBC ≥ 75 % blast , bone marrow aspiration omit medical contraindication Immunophenotype Wright 's stain morphology blast cell consistent acute lymphocytic leukemia ≤ 21 year age time diagnosis No previous registration 9900 Samples must send local institution COG Reference Laboratory study NOTE : *It urge bone marrow aspiration perform every patient suspect ALL . However , marrow require patient ≥ 100,000/μl peripheral blood WBC ≥ 75 % blast patient whose clinical condition precludes perform procedure safely . Patients medical contraindication procedure must discuss one study coordinator must peripheral blood WBC ≥ 30,000/μl ≥ 75 % blast . Induction therapy study : Patients must confirm diagnosis Bprecursor acute lymphoblastic leukemia Patients must 1.001 21.999 year diagnosis NOTE : Patients meet eligibility criterion eligible registration 9900 whether enter COG frontline protocol treatment newly diagnose ALL . Registration 9900 require legacy POG institution patient order eligible entry follow COG ALL study , either currently open temporarily close : P9407 , 9904 , 9905 , 9907 , AALL0031 AALL00P2 . PATIENT CHARACTERISTICS : See Disease Characteristics PRIOR CONCURRENT THERAPY : Previously untreated , follow exception : Steroid treatment* 48hour period prior study entry allow provided physical examination CBC differential perform IMMEDIATELY prior begin steroids result know NOTE : *Patients chronic steroid treatment another disease NOT eligible COG New ALL protocol .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>non-T , non-B , cALLa positive , pre-B childhood acute lymphoblastic leukemia</keyword>
</DOC>